Lan Chen

Title: Innovations of Lan Chen in Antibody Development

Introduction

Lan Chen is a notable inventor based in Chengdu, China, recognized for his contributions to the field of biopharmaceuticals. He has been instrumental in developing innovative antibody technologies that have significant implications for therapeutic applications. With a total of three patents to his name, Chen's work focuses on enhancing the efficacy and specificity of antibody-based treatments.

Latest Patents

One of Lan Chen's latest patents is titled "Bispecific tetravalent antibodies and methods of making and using thereof." This invention describes a bispecific tetravalent antibody that comprises an IgG with a pair of heavy chains and light chains, along with two scFv components connected to either the C or N terminals of the chains. This antibody exhibits binding specificity for two different members of the EGFR family, which is crucial for targeted cancer therapies.

Another significant patent is the "Cysteine modified antibody-drug conjugate and preparation method thereof." This innovation involves inserting cysteine into a heavy chain and/or light chain of a target antibody at specific insertion sites. The method allows for site-specific conjugation through a free thiol group from the inserted cysteine and a linker conjugated with a potent small molecule cytotoxin. This results in a cysteine modified antibody-drug conjugate with improved homogeneity, enhancing its therapeutic potential.

Career Highlights

Lan Chen has worked with several prominent companies in the biopharmaceutical sector, including Systimmune, Inc. and Sichuan Baili Pharmaceutical Co. Ltd. His experience in these organizations has allowed him to refine his expertise in antibody engineering and drug development.

Collaborations

Throughout his career, Lan Chen has collaborated with talented individuals such as Shi Zhuo and Yi Zhu. These partnerships have contributed to the advancement of his research and the successful development of innovative therapeutic solutions.

Conclusion

Lan Chen's work in the field of antibody development showcases his commitment to advancing biopharmaceutical innovations. His patents reflect a deep understanding of antibody engineering and its potential to improve therapeutic outcomes.